Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptor, in the prevention of relapse of depression following successful response. METHOD: Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a 24-week, randomized, double-blind treatment period. The main outcome measure was time to relapse during the double-blind treatment period. The cumulative probability of relapse was calculated using the Kaplan-Meier method of survival analysis. The study was conducted from February 2005 to February 2007. RESULTS: During the 6-month evaluation period, the incidence of relapse was significantly lower in patients who continued treatment than in those switched to placebo (P=.0001). The cumulative relapse rate at 6 months for agomelatine-treated patients was 21.7%; that for placebo-treated patients was 46.6%. Agomelatine was also superior to placebo in preventing relapse in the subset of patients with baseline 17-item Hamilton Depression Rating Scale total score > or = 25. Measures of tolerability and safety of both doses of agomelatine were similar to placebo. No pattern of early relapse or adverse events suggestive of withdrawal symptoms was obtained after abrupt cessation of agomelatine. CONCLUSIONS: The findings are important in 2 respects. First, agomelatine is an effective and safe antidepressant continuation therapy, which confirms efficacy seen in short-term studies. Second, few early relapses were observed in the patient group switched to placebo: the survival curve for placebo separated gradually from that of patients taking agomelatine. We suggest this reflects solely the underlying properties of the illness, which is only possible due to the lack of discontinuation syndrome after agomelatine withdrawal. It underlines the novel clinical profile of agomelatine, which quite likely reflects its innovative pharmacology. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN53193024.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Suicide/suicide attempt is mentioned 19 times (1, 15, 16, 18, 19, 26, 27, 33, 37, 38, 41, 43–46, 48–50, 52)”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [37]
In the citing paper
“Two DBRPCTs on agomelatine had inconsistent results [32, 33].”
From Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (2023) · cites this paper as [33]
In the citing paper
“In 1980 and 1990s, Dilsaver documented general somatic and gastrointestinal distress; sleep disturbances characterized by initial and middle insomnia or excessively vivid and frightening dreams; akathisia or parkinsonism; hypomania or mania as manifestations of new withdrawal symptoms due to TCA discontinuation [92-95].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [92]
Citations
Cites
Still being checked.
Cited by
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…dysfunction is less likely than with SSRI or SNRI antidepressants [I (M)] (Serretti and Chiesa, 2009), as are discontinuation symptoms [I (PCT)] (Goodwin et al., 2009; Montgomery et al., 2004): elevations of hepatic enzymes occur in more than 1% of treated patients and regular monitoring of…”
BackgroundAgomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Serotonin Receptors – From Molecular Biology to Clinical Applications
PYTLIAK, M., VARGOVÁ, V., MECHÍROVÁ, V., & FELŠÖCI, M. (2011) · Physiological Research · doi:10.33549/physiolres.931903 · Cited by 318
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera-Salva, M.-A., Wirz-Justice, A. M., Picarel-Blanchot, F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05347blu · Cited by 257
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“…described with all classes of antidepressants, including TCAs (particularly those with anticholinergic and serotonergic potency), irreversible MAO inhibitors, SSRIs and venlafaxine (Lejoyeux and Ades 1997; Edwards and Anderson 1999), but not with agomelatine (Goodwin et al. 2009) or vortioxetine.”
BackgroundInfluence of the modern light environment on mood
Bedrosian, T. A., & Nelson, R. J. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.70 · Cited by 172
Bedrosian, T. A., Fonken, L. K., Walton, J. C., Haim, A., & Nelson, R. J. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.01.004 · Cited by 167
New targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Agomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness
Kennedy, S. H., & Rizvi, S. J. (2010) · CNS Drugs · doi:10.2165/11534420-000000000-00000 · Cited by 160
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
“Two DBRPCTs on agomelatine had inconsistent results [32, 33].”
ResultHale, A., Corral, R.-M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833a86aa · Cited by 127
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 144
Fornaro, M., Prestia, D., Colicchio, S., & Perugi, G. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246227 · Cited by 119
Antidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
Chronic dim light at night provokes reversible depression-like phenotype: possible role for TNF
Bedrosian, T. A., Weil, Z. M., & Nelson, R. J. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.96 · Cited by 112
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103
Therapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
Circadian Rhythms, Melatonin and Depression
A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197188 · Cited by 100
Agomelatine versus other antidepressive agents for major depression
Guaiana, G., Gupta, S., Chiodo, D., Davies, S. J., Haederle, K., & Koesters, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008851.pub2 · Cited by 74
Rotroff, D. M., Corum, D. G., Motsinger-Reif, A., Fiehn, O., Bottrel, N., Drevets, W. C., Singh, J., Salvadore, G., & Kaddurah-Daouk, R. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.145 · Cited by 95
Koesters, M., Guaiana, G., Cipriani, A., Becker, T., & Barbui, C. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.120196 · Cited by 93
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Weight Considerations in Psychotropic Drug Prescribing and Switching
Hasnain, M., & Vieweg, W. V. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2706 · Cited by 86
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
De Berardis, D., Marini, S., Fornaro, M., Srinivasan, V., Iasevoli, F., Tomasetti, C., Valchera, A., Perna, G., Quera-Salva, M.-A., Martinotti, G., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612458 · Cited by 83
Agomelatine: A narrative review
Demyttenaere, K. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.004 · Cited by 90
Yatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.147587 · Cited by 79
Self-citationCircadian dimension and severity of depression
Courtet, P., & Olié, É. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.009 · Cited by 93
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review
Pompili, M., Serafini, G., Innamorati, M., Venturini, P., Fusar-Poli, P., Sher, L., Amore, M., & Girardi, P. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.765593 · Cited by 78
A systematic review of agomelatine-induced liver injury
Freiesleben, S. D., & Furczyk, K. (2015) · Journal of Molecular Psychiatry · doi:10.1186/s40303-015-0011-7 · Cited by 77
The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
De Berardis, D., Di Iorio, G., Acciavatti, T., Conti, C., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Saverio Moschetta, F., et al. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488674 · Cited by 76
De Berardis, D., Fornaro, M., Serroni, N., Campanella, D., Rapini, G., Olivieri, L., Srinivasan, V., Iasevoli, F., Tomasetti, C., De Bartolomeis, A., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011111 · Cited by 75
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 70
Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress
Dagytė, G., Crescente, I., Postema, F., Seguin, L., Gabriel, C., Mocaër, E., Boer, J. A. D., & Koolhaas, J. M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.045 · Cited by 69
Dagytė, G., Trentani, A., Postema, F., Luiten, P. G., Den Boer, J. A., Gabriel, C., Mocaër, E., Meerlo, P., & Van der Zee, E. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00125.x · Cited by 68
Mocaër, E., Dagytė, G., Crescente, I., Postema, F., Seguin, L., Gabriel, C., den Boer, J. A., & Koolhaas, J. M. (2011) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(11)70669-1 · Cited by 65
Gałecki, P., Szemraj, J., Bartosz, G., Bieńkiewicz, M., Gałecka, E., Florkowski, A., Lewiński, A., & Karbownik‐Lewińska, M. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00754.x · Cited by 64
Depression in primary care: part 2—management
Ramanuj, P., Ferenchick, E. K., & Pincus, H. A. (2019) · BMJ · doi:10.1136/bmj.l835 · Cited by 78
Agomelatine for depression: expanding the horizons?
Norman, T. R., & Olver, J. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574747 · Cited by 75
Anhedonia and major depression: The role of agomelatine
Giannantonio, M. D., & Martinotti, G. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.004 · Cited by 68
A critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Howland, R. H. (2011) · Drug Safety · doi:10.2165/11593960-000000000-00000 · Cited by 67
Agomelatine: a novel antidepressant.
Sansone, R. A., & Sansone, L. A. (2011) · Europe PMC (PubMed Central) · Cited by 74
Millan, M. J., Marin, P., Kamal, M. T., Jockers, R., Chanrion, B., Labasque, M., Bockaert, J., & la Cour, C. M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001045 · Cited by 61
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal
Singh, S. P., Singh, V., & Kar, N. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001301 · Cited by 60
Tardito, D., Milanese, M., Bonifacino, T., Musazzi, L., Grilli, M., Mallei, A., Mocaër, E., Gabriel, C., Racagni, G., Popoli, M., et al. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-68 · Cited by 61
Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action
Srinivasan, V., Zakaria, R., Othman, Z., Lauterbach, E. C., & Acuña-Castroviejo, D. (2012) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11090216 · Cited by 66
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
Emerging antidepressants to treat major depressive disorder
Block, S. G., & Nemeroff, C. B. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.09.001 · Cited by 61
Prescriber's Guide: Stahl's Essential Psychopharmacology
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 87
Ladurelle, N., Gabriel, C., Viggiano, A., Mocaër, E., Baulieu, E. E., & Bianchi, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2597-5 · Cited by 53
The effects of agomelatine on sexual function in depressed patients and healthy volunteers
Montejo, A., Majadas, S., Rizvi, S. J., & Kennedy, S. H. (2011) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1243 · Cited by 51
The use of antidepressants in clinical practice: focus on agomelatine
McAllister‐Williams, R. H., Baldwin, D. S., Haddad, P. M., & Bazire, S. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1094 · Cited by 48
Review: Restoring circadian rhythms: a new way to successfully manage depression
Gorwood, P. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372981 · Cited by 47
Agomelatine for the treatment of major depressive disorder
Carney, R. M., & Shelton, R. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.607812 · Cited by 45
Fornaro, M. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-5 · Cited by 42
Ramírez-Rodríguez, G. B., Vega‐Rivera, N. M., Oikawa‐Sala, J., Gómez‐Sánchez, A., Ortíz‐López, L., & Estrada-Camarena, E. M. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12136 · Cited by 42
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Melatonin and agomelatine for preventing seasonal affective disorder
Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Sonis, J. H., Greenblatt, A., Wipplinger, J., Lux, L. J., Winkler, D., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011271.pub2 · Cited by 39
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Poleszak, E., Szopa, A., Wyska, E., Kukuła‐Koch, W., Serefko, A., Wośko, S., Bogatko, K., Wróbel, A., & Właź, P. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.06.138 · Cited by 39
The preclinical discovery and development of agomelatine for the treatment of depression
Konstantakopoulos, G., Dimitrakopoulos, S., & Michalopoulou, P. G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1781087 · Cited by 41
Howland, R. H. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5453 · Cited by 42
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Gahr, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12999140619122914 · Cited by 37
Huang, K., Lu, W., Wang, Y.-Y., Hu, G., Lu, C.-H., Lee, W., & Hsu, C. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414525837 · Cited by 41
Sun, X., Wang, M., Wang, Y., Lian, B., Sun, H., Wang, G., Li, Q., & Sun, L. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.015 · Cited by 40
Green, B. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.554534 · Cited by 35
Moll, J. L., & Brown, C. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02190.x · Cited by 36
Agomelatine: The Novel Antidepressant
Sup, W. Y., 왕희령, & Bahk, W. (2014) · 대한정신약물학회지 · Cited by 34
Mood Disorders, Circadian Rhythms, Melatonin and Melatonin Agonists
Quera-Salva, M.-A., & Hartley, S. (2012) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4103 · Cited by 34
Dagyte, G., Luiten, P. G., De Jager, T., Gabriel, C., Mocaër, E., Den Boer, J. A., & Van der Zee, E. A. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22697 · Cited by 32
“Agomelatine has shown efficacy in treatment of major depressive disorder (Kennedy and Emsley, 2006; Olie and Kasper, 2007; Goodwin et al., 2009).”
BackgroundLlorca, P. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372978 · Cited by 33
Agomelatine Is Effective in Reducing Insomnia in Abstinent Alcohol-Dependent Patients
Grosshans, M., Mutschler, J., Luderer, M., Mann, K. F., & Kiefer, F. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000007 · Cited by 31
Santos, P. C. D., Herrmann, A. P., Elisabetsky, E., & Piato, Â. (2018) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0005 · Cited by 37
Perlemuter, G., Cacoub, P., Valla, D. C., Guyader, D., Saba, B., Batailler, C., & Moore, K. P. (2016) · CNS Drugs · doi:10.1007/s40263-016-0351-6 · Cited by 29
Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.217 · Cited by 30
Efficacy and tolerability of agomelatine in the treatment of depression
Plesničar, B. K. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s42789 · Cited by 35
Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140208 · Cited by 33
Manipulating melatonin in managing mood
Boyce, P., & Hopwood, M. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12175 · Cited by 27
Medvedev, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s129793 · Cited by 29
Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
Savino, R., Polito, A. N., Marsala, G., Ventriglio, A., Salvatore, M. D., de Stefano, M. I., Valenzano, A. A., Marinaccio, L., Bellomo, A., Cibelli, G., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13050734 · Cited by 30
Norman, T. R., Cranston, I., Irons, J. A., Gabriel, C., Dekeyne, A., Millan, M. J., & Mocaër, E. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.010 · Cited by 36
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Agomelatine: Efficacy at Each Phase of Antidepressant Treatment
Kennedy, S. H. (2009) · CNS Drugs · doi:10.2165/11318660-000000000-00000 · Cited by 29
The mechanism, efficacy, and tolerability profile of agomelatine
MacIsaac, S. E., Carvalho, A. F., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.862233 · Cited by 24
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Yacoubi, M. E., Dubois, M., Gabriel, C., Mocaër, E., & Vaugeois, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.001 · Cited by 27
New Therapeutic Strategy for Mood Disorders
Crupi, R., Marino, A., & Cuzzocrea, S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797200417 · Cited by 23
Smeraldi, E., & Delmonte, D. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.828690 · Cited by 28
Opioid system mediated anti-nociceptive effect of agomelatine in mice
Kasap, M., & Can, Ö. D. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.031 · Cited by 21
Soini, E. J., Hallinen, T., Brignone, M., Campbell, R., Diamand, F., Cure, S., Aalto-Setälä, M., Danchenko, N., Koponen, H., & Kolasa, K. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1240617 · Cited by 22
Clinical Studies on the Efficacy of Agomelatine on Depressive Symptoms
Goodwin, G. M. (2009) · CNS Drugs · doi:10.2165/11318650-000000000-00000 · Cited by 21
Self-citation
Metadata
- Authors
- Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group
- Affiliations
- Warneford Hospital (GB)
- Corresponding author
- Goodwin, Guy M.
- ORCID
- Goodwin, Guy M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-08-11
- Volume
- 70
- Issue
- 8
- Pages
- 1128-1137
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059735897
- Semantic Scholar
- 1bd98c3c9aff0e1628639bd92c7138577e80d1c8
- Cited by
- 340
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 164 · 2019: 10 · 2018: 3 · 2017: 7 · 2016: 12 · 2015: 13 · 2014: 14 · 2013: 19 · 2012: 16
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- agomelatine, major depressive disorder, relapse prevention, continuation treatment, discontinuation syndrome, 5-HT2C receptor antagonism, antidepressant efficacy, placebo response, early recurrence
- MeSH terms
- Acetamides, Adolescent, Adult, Aged, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypnotics and Sedatives, Male, Melatonin, Middle Aged, Naphthalenes, Substance Withdrawal Syndrome, Treatment Outcome, Receptor, Melatonin, MT1, Receptor, Melatonin, MT2, Kaplan-Meier Estimate, Secondary Prevention, Serotonin 5-HT2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.